Abstracts tagged "radiography and rheumatoid arthritis"

Abstract Number: 2520 • 2016 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab
Cecilie Heegaard Brahe¹, Mikkel Østergaard², Julia Sidenius Johansen³, Nadine A. Defranoux⁴, Ching Chang Hwang⁵, Xingbin Wang⁴, Rebecca J. Bolce⁴, Eric H. Sasso⁴, Kim Hørslev-Petersen⁶, Kristian Stengaard-Pedersen⁷, Lykke Midtbøll Ørnbjerg⁸, Peter Junker⁹, Torkell Ellingsen¹⁰, Palle Ahlquist¹¹, Hanne Lindegaard¹², Asta Linauskas¹³, Annette Schlemmer¹⁴, Mette Yde Dam¹⁵, Ib Tønder Hansen¹⁶, Tine Lottenburger¹¹, Christian G. Ammitzbøll¹⁷, Anette Jørgensen¹⁷, Sophine B. Krintel⁸, Johnny Lillelund Raun¹⁸ and Merete Lund Hetland^3,19, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ³Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ⁴Crescendo Bioscience Inc., South San Francisco, CA, ⁵Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁶King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁷Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Copenhagen, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁹Department of Rheumatology C, Odense University Hospital, Odense, Denmark, ¹⁰Department of Rheumatology, Odense University Hospital, Odense, DK, Odense, Denmark, ¹¹Department of Medicine, Vejle Regional Hospital, Vejle, Denmark, ¹²The DANBIO registry and the Danish Departments of Rheumatology, Odense, Denmark, ¹³The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ¹⁴9Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁵Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, ¹⁶Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹⁷Department of Rheumatology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark, ¹⁸King Christian X Hospital for Rheumatic Diseases, South Jutland Hospital, Graasten, Denmark, ¹⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark,, Copenhagen, Denmark
Background/Purpose: The multi-biomarker disease activity (MBDA) score, which combines 12 serum biomarkers to measure RA disease activity on a scale of 1−100, has been found…
Abstract Number: 2729 • 2015 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis
Tsuneo Kondo, Akiko Shibata, Ryota Sakai, Jun Kikuchi, Kentaro Chino, Ayumi Okuyama, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…
Abstract Number: 359 • 2012 ACR/ARHP Annual Meeting
Improved Radiological Outcome of Rheumatoid Arthritis: Early Treatment with methotrexate might be a key Prognostic Factor
Christoph Fiehn¹, Elisabeth Belke-Voss¹, Dietmar Krause², Siegfried Wassenberg³ and Rolf Rau⁴, ¹ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ²Dept. for Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany, ³Rheumaklinik, Evangelisches Fachkrankenhaus Ratingen, Rheumazentrum, Ratingen, Germany, ⁴Düsseldorf, Germany
Background/Purpose: To compare the rate of radiological progression in patients with rheumatoid arthritis (RA) diagnosed in the 1980s with those of the late 1990s until…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].